Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Toxin Mechanisms and Immunotoxins

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the development and efficacy of immunotoxin therapy for cancer treatment, with a particular emphasis on ricin poisoning, ribosome-inactivating proteins, and targeted therapy using recombinant immunotoxins. It also explores the use of IL-13 receptor and mistletoe extract in cancer therapy.

102
Works

How has Toxin Mechanisms and Immunotoxins's publication output changed over time?

ScholarIQpublication output · 1999–2017

Output grew0% over the shown period — from 1 works in 1999 to 1 in 2017.

1
1
1
2
2
1
1
1
1
1
1999200120022003200520112013201420162017

What are the most-cited papers on Toxin Mechanisms and Immunotoxins?

ScholarIQmost cited works
IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis
Stefan Fichtner‐Feigl, Warren Strober, Koji Kawakami, Raj K. Puri, Atsushi Kitani
Nature Medicine. 2005884 Citations
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Garth Powis, Rosanne Bonjouklian, Margareta Berggren, Alfred Gallegos, Robert T. Abraham, Curtis L. Ashendel, Leon H. Zalkow, William F. Matter, Jeffrey A. Dodge, Gerald B. Grindey
PubMed. 1994692 Citations
Ricin Poisoning
Jennifer Audi, Martin Belson, Manish M. Patel, Joshua G. Schier, John Osterloh
JAMA. 2005627 Citations
The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer
E Asbrink, A. Hovmark, B Hederstedt
Acta Dermato Venereologica. 1984221 CitationsOPEN ACCESS

Where is Toxin Mechanisms and Immunotoxins research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation
NIH
Wellcome Trust
European Research Council
Funder breakdown is a member featureSign up free to unlock

How much of the research on Toxin Mechanisms and Immunotoxins is open access?

ScholarIQopen access share
47%OPEN ACCESS
Gold
7%
Green
13%
Hybrid
13%
Bronze
13%
Closed
53%

Related on ScholarIQ

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Paper
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
Paper
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo
Paper
IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis
Paper
Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
Paper
Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes.
Paper
470M+ articles · free account